Summary
UniQure NV (UniQure) formerly uniQure BV is a pharmaceutical company that develops and markets gene therapy products. The company develops adeno-associated virus based gene therapies by using its modular technology platform. Its glybera is used to restore the LPL enzyme activity. UniQure offers clinical and preclinical programs for lipoprotein lipase deficiency, hemophilia B, sanfilippo B syndrome, acute intermittent porphyria, congestive heart failure and Parkinson’s disease. UniQure is also developing gene therapies for cardiovascular diseases. The company conducts drug discovery and preclinical research in collaboration with academic research institutions. UniQure is headquartered in Amsterdam, the Netherlands.
UniQure NV (QURE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
'
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
UniQure NV, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 6
UniQure NV, Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 7
UniQure NV, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 8
UniQure NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 9
UniQure NV, Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 10
UniQure NV, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
uniQure Raises Additional USD10 Million in Venture Debt Financing 12
uniQure Raises US$10 Million In Venture Financing 13
UniQure Raises USD17.5 Million in Venture Financing 14
Partnerships 16
Bristol-Myers Squibb Enters into Agreement with uniQure 16
Synpromics Extends Co-Development Agreement with uniQure for Gene Therapy Vector 18
uniQure Enters Into Co-Marketing Agreement With Chiesi Farmaceutici 19
uniQure Enters Into Agreement With University of California, San Francisco To Develop Gene Therapy For Parkinson Disease 21
Amsterdam Molecular Therapeutics Enters Into An Agreement With Institut Pasteur And The Consortium 23
Licensing Agreements 24
uniQure Enters into Licensing Agreement with 4D Molecular Therapeutics 24
uniQure Enters into Licensing Agreement with Protein Sciences 25
Treeway Enters into Licensing Agreement with uniQure 26
uniQure Enters Into Licensing Agreement With Benitec Biopharma For RNA Interference Technology 27
Benitec Biopharma Enters Into Licenising Agreement With uniQure 28
uniQure Enters Into Licensing Agreement With Protein Sciences For expresSF+ Insect Cell Technology 29
Amsterdam Molecular Expands Licensing Agreement With National Institutes Of Health 30
Amsterdam Molecular Enters Into Licensing Agreement With National Institutes Of Health 31
Equity Offering 32
uniQure Raises USD38 Million in Private Placement of Shares 32
uniQure Raises USD88.5 Million in Public Offering of Shares 33
uniQure Completes IPO For US$91.8 Million 35
uniQure Announces Private Placement Of Shares For US$7.8 Million 37
Acquisition 38
UniQure Acquires InoCard for USD4 Million 38
uniQure Acquires Amsterdam Molecular Therapeutics, Developer Of Gene Therapy 39
UniQure NV - Key Competitors 41
Key Employees 42
Locations And Subsidiaries 43
Head Office 43
Other Locations & Subsidiaries 43
Appendix 44
Methodology 44
About GlobalData 44
Contact Us 44
Disclaimer 44
List of Tables
UniQure NV, Pharmaceuticals & Healthcare, Key Facts, 2015 1
UniQure NV, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 6
UniQure NV, Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 7
UniQure NV, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 8
UniQure NV, Deals By Therapy Area, 2010 to YTD 2016 9
UniQure NV, Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 10
uniQure Raises Additional USD10 Million in Venture Debt Financing 12
uniQure Raises US$10 Million In Venture Financing 13
UniQure Raises USD17.5 Million in Venture Financing 14
Bristol-Myers Squibb Enters into Agreement with uniQure 16
Synpromics Extends Co-Development Agreement with uniQure for Gene Therapy Vector 18
uniQure Enters Into Co-Marketing Agreement With Chiesi Farmaceutici 19
uniQure Enters Into Agreement With University of California, San Francisco To Develop Gene Therapy For Parkinson Disease 21
Amsterdam Molecular Therapeutics Enters Into An Agreement With Institut Pasteur And The Consortium 23
uniQure Enters into Licensing Agreement with 4D Molecular Therapeutics 24
uniQure Enters into Licensing Agreement with Protein Sciences 25
Treeway Enters into Licensing Agreement with uniQure 26
uniQure Enters Into Licensing Agreement With Benitec Biopharma For RNA Interference Technology 27
Benitec Biopharma Enters Into Licenising Agreement With uniQure 28
uniQure Enters Into Licensing Agreement With Protein Sciences For expresSF+ Insect Cell Technology 29
Amsterdam Molecular Expands Licensing Agreement With National Institutes Of Health 30
Amsterdam Molecular Enters Into Licensing Agreement With National Institutes Of Health 31
uniQure Raises USD38 Million in Private Placement of Shares 32
uniQure Raises USD88.5 Million in Public Offering of Shares 33
uniQure Completes IPO For US$91.8 Million 35
uniQure Announces Private Placement Of Shares For US$7.8 Million 37
UniQure Acquires InoCard for USD4 Million 38
uniQure Acquires Amsterdam Molecular Therapeutics, Developer Of Gene Therapy 39
UniQure NV, Key Competitors 41
UniQure NV, Key Employees 42
UniQure NV, Other Locations 43
UniQure NV, Subsidiaries 43
List of Figures
UniQure NV, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 1
UniQure NV, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 1
UniQure NV, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 1
UniQure NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 1
UniQure NV, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 6
UniQure NV, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 7
UniQure NV, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 8
UniQure NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 9
